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Background:We hypothesized that higher concentrations of LDL particles (LDL-P) and leptin, and lower con-
centrations of HDL particles (HDL-P), and total and high molecular weight (HMW) adiponectin, would pre-
dict incident coronary heart disease (CHD) among severely obese postmenopausal women.
Methods: In a case–cohort study nested in the Women's Health Initiative Observational Study, we sampled
677 of the 1852 white or black women with body mass index (BMI) ≥40 kg/m2 and no prevalent cardiovas-
cular disease (CVD), including all 124 cases of incident CHD over mean 5.0 year follow-up. Biomarkers were
assayed on stored blood samples.
Results: In multivariable-adjusted weighted Cox models, higher baseline levels of total and small LDL-P, and
lower levels of total and medium HDL-P, and smaller mean HDL-P size were signiﬁcantly associated with
incident CHD. In contrast, large HDL-P levels were inversely associated with CHD only for women without
diabetes, and higher total and HMW adiponectin levels and lower leptin levels were associated with CHD
only for women with diabetes. Higher total LDL-P and lower HDL-P were associated with CHD risk indepen-
dently of confounders including CV risk factors and other lipoproteinmeasures, with adjusted HR (95% CIs) of
1.55 (1.28, 1.88) and 0.70 (0.57, 0.85), respectively, and similar results for medium HDL-P.
Conclusions:Higher CHD risk among severely obese postmenopausal women is strongly associatedwithmod-
iﬁable concentrations of LDL-P and HDL-P, independent of diabetes, smoking, hypertension, physical activity,from the National Heart, Lung, and Blood Institute (NHLBI) to Dr. Mackey. The WHI program is funded by the National Heart,
, and U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C,
201100004C, and HHSN271201100004C. The complete list of WHI centers and investigators can be found online at http://
ch grant from LipoScience, Inc. to theUniversity of Pittsburgh. LipoScience had no involvement in that study or the current study
ry measurements. RM has received honoraria from the National Lipid Association for educational (non-promotional) activities.
raduate School of Public Health, 542 Belleﬁeld Professional Building, 130 N. Belleﬁeld Ave, Pittsburgh, PA 15213, United States.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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General signiﬁcance: Severely obese postmenopausal women should be considered high risk candidates for
lipid lowering therapy.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionFig. 1. Selection of case–cohort study participants from theWomen's Health Initiative Ob-
servational Study (WHI-OS). The subcohort was selected without regard to incident CHD
using stratiﬁed randomsampling to obtain approximately equal numbers in strata deﬁned
by ethnicity, waist circumference tertiles (waist circumference [WC] b 111.6, 111.6–b121
and ≥121 cm), and age groups: 50–59, 60–69 and 70–79.The prevalence of extreme, or severe, obesity (body mass index
[BMI] ≥ 40 kg/m2) [1] is higher for women than men, and for black
than white women among US adults [2]. We have previously shown
that among postmenopausal women in the Women's Health Initiative
(WHI), incident coronary heart disease (CHD) and total mortality
rates are doubled for severe obesity compared with normal BMI [3]. In
WHI, within the category of severe obesity, CHD incidence was unrelat-
ed to BMI, but was strongly associated with smoking, diabetes, and
hypertension [3]. Similarly, among severely obese adults in the Swedish
Obesity Study (SOS), risk ofmyocardial infarction (MI) and cardiovascu-
lar disease (CVD) were not related to BMI, but were related to diabetes,
smoking, systolic blood pressure (SBP), and total cholesterol [4].
However, individuals with severe obesity are rarely included in non-
bariatric surgery cohort studies, so that there is little data on CVD risk
factors among women with severe obesity, particularly for novel
biomarkers [5].
Obesity is strongly related to higher levels of leptin and lower levels
of total and high molecular weight (HMW) adiponectin, all of which
have been proposed as risk factors and possible therapeutic targets for
the prevention of obesity or its metabolic and cardiovascular effects.
Although several studies have reported that higher leptin levelswere as-
sociatedwith increased CHD risk, ameta-analysis suggested that the risk
was largely dependent on the strong association of leptin with BMI [6].
Adiponectin, both the total and the HMW form, are inversely associated
with obesity and particularly with insulin resistance, but associations
are mixed in relation to CHD and mortality [7–9]. The SOS has reported
that higher baseline and greater 2 year increases in adiponectinwere as-
sociatedwith lower CHD risk for severely obese patientswho did not re-
ceive bariatric surgery, but not for those who did [10]. However, the
relation of leptin, and total andHMWadiponectin to CHDrisk among se-
verely obese postmenopausal women remains unclear.
Finally, associations with CHD events are similar or stronger for
concentrations of low density lipoprotein particles (LDL-P) and high
density lipoprotein (HDL) particles (HDL-P) compared with concentra-
tions of the cholesterol carried by those particles, i.e., LDL cholesterol
(LDL-C) andHDL-C [11–16]. Under- or over-estimation of atherosclerot-
ic CHD risk by LDL-C comparedwith LDL-P or apoB, which approximates
LDL-P, is common, particularly amongpostmenopausalwomen [15–17].
In the Dallas Heart Study, HDL-P was similarly associated with lower
CHD risk among white and black participants, but HDL-C was not asso-
ciated with CHD risk among black participants, who had higher HDL-C
and larger mean HDL size than white participants [18]. Smaller LDL
andHDL particle sizes are also associated with incident CVD, but several
studies have shown that these associations are not independent of
correlated levels of total LDL-P, apoB, apoA-1 or HDL-P [12,14,19–22].
However, associations of LDL-P andHDL-P, subclasses andmean particle
sizes with incident CHD in severe obesity have not been reported.
Therefore we conducted a case–cohort study nested in the WHI
Observational Study (WHI-OS), to evaluate concentrations of lipopro-
tein particles, total and HMW adiponectin, leptin, as predictors of
incident CHD among black and white postmenopausal women with
severe obesity. Speciﬁcally, we hypothesized that among severely
obese postmenopausal women without baseline CVD, incident CHD
would be related to lower levels of total and HMW adiponectin, and tohigher levels of leptin, independent of BMI and diabetes, but that higher
levels of total LDL-P and lower levels of total HDL-P would be the stron-
gest determinants of incident CHD.2. Methods
2.1. Participants and data
The 677 participants in the current case–cohort studywere sampled
from the WHI-OS (Fig. 1). As previously described in detail [23], the
WHI-OS recruited 93,676 postmenopausal women aged 50 to 79 at 40
centers in the United States between 1993 and 1998 who chose not to
or were ineligible to participate in WHI hormone or diet clinical trials.
The current study was restricted to the 1852 black and white postmen-
opausal women inWHI-OS with BMI≥ 40 kg/m2 and no prevalent CVD
(MI, angina, revascularization, congestive heart failure, stroke or periph-
eral vascular disease) and sufﬁcient blood sample. According to case–
cohort methodology [24], a subcohort (n = 579) was sampled from
this subset without regard to incident CHD, using stratiﬁed random
sampling to obtain approximately equal numbers in strata deﬁned by
ethnicity, waist circumference tertiles (waist circumference [WC]
b111.6, 111.6–b121 and ≥121 cm), and age groups: 50–59, 60–69
and 70–79 (see Fig. 1). Incident CHDeventswere deﬁned as adjudicated
fatal and non-fatal MI, angina and/or angioplasty and bypass surgery
[25]. All cases of incident CHD that occurred after the baseline blood
draw date through August 2006 were also selected, n = 124, of whom
26 had also been selected in the subcohort, per case–cohort design
[24]. Participants provided informed consent and institutional review
Table 1
Characteristics of 677 postmenopausal women with BMI ≥ 40 kg/m2, by incident CHD.
Characteristica No CHD (n = 553) Incident CHD (n = 124)
White/Black, nb 264/289 101/23
Age, yearsb 65.2 (6.9) 64.6 (6.9)
BMI, kg/m2 44.4 (4.1) 44.4 (4.5)
Waist circumference, cmb 117.1 (10.7) 119.8 (10.1)
Physical activity, met/h/wk 6.2 (9.7) 5.3 (8.3)
Diabetes, % 28.6 42
Hypertension, % 76.1 76.0
Smoking, %
Never 52.0 51.2
Prior 44.1 40.5
Current 3.9 8.3
Current hormone use, % 33.7 23.4
Lipid-lowering treatment,% 14.6 19.4
a Values are mean (SD) unless indicated as %.
b Subcohort sampling was stratiﬁed by race-ethnicity, age-group and waist circumfer-
ence, accounted for in analyses by weighted regression analyses.
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study. At baseline and 3 year follow-up clinic visits, data was collected
on demographics, medical history, medications (including hormone
therapy (HT)), measured height, weight and blood pressure. Blood
was drawn after aminimum10h of fasting, and serumand plasma sam-
ples were frozen and stored at−70 °C in a central repository [23]. Hy-
pertension (systemic) was deﬁned as SBP ≥ 140 mm Hg or diastolic
blood pressure (DBP) ≥ 90 mm Hg or use of antihypertensive therapy
[26]. Type 2 diabetes was deﬁned as history of Type 2 diabetes, use of
diabetic medications, or glucose≥126mg/dl [27]. Recreational physical
activity was calculated from self-report based on a structured question-
naire, deﬁned as expenditure of energy from recreational physical activ-
ity (includes walking, mild, moderate and strenuous physical activity)
and expenditure of energy was estimated by total METs per week
(kcal/week per kg), as previously described in detail [23].
2.2. Biomarker quantiﬁcation
To conserve baseline samples, stored specimens from the year 3
follow-up visit were used, except for participants with inadequate spec-
imen volume (n=70), for whombaseline stored specimenswere used.
The visit concurrent with biospecimen collection was deﬁned as base-
line for case ascertainment and for other study data, except for time-
independent variables (e.g., race), fromWHI baseline. UnderWHI coor-
dinating center oversight, stored specimens were thawed, aliquoted
(vials coded to blind study investigators/laboratories to participant
identiﬁers), and shipped on dry ice to the Heinz Laboratory at the Uni-
versity of Pittsburgh Graduate School of Public Health, and to
LipoScience, Inc., Raleigh, NC. The Heinz Laboratory assayed serum
glucose by enzymatic methods; serum leptin, and insulin via standard
radioimmunoassay (RIA) kits (Linco Research, Inc., St. Charles, MS);
and total and HMW adiponectin via ELISA (ALPCO Diagnostics, Salem,
NH). The intra- and inter-assay coefﬁcients of variation were, respec-
tively, 1.3% and 2.2% for glucose; 5.6% and 8.2% for insulin; 6.6% and
5.5% for leptin; 6.4% and 12.7% for total adiponectin; and 6.4% and
12.6% for HMW adiponectin. LipoScience, Inc. determined plasma lipo-
protein subclasses using an automated nuclear magnetic resonance
(NMR) spectroscopic assay (Lipoproﬁle III), as previously described in
detail [28,29]. Particle concentrations of the different-sized lipoprotein
subclasses were derived from the measured amplitudes of the charac-
teristic lipid methyl group NMR signals they emit. Subclasses were
summed to provide concentrations of total LDL-P, total HDL-P and
total very large LDL particles (VLDL-P). Mean LDL-P and HDL-P sizes
are weighted-averages (i.e., the diameter of each subclass multiplied
by its relative concentration.) Inter-assay reproducibility (coefﬁcient
of variation), determined from 80 replicate analyses of 8 plasma pools
over 20 days, was 8, 3, and 2% for total VLDL-P, LDL-P, and HDL-P;
0.7% for LDL and HDL size; 4% for VLDL size; 7, 13, and 22% for large,
medium, and small VLDL-P; 43, 12, and 10% for IDL-P, large, and small
LDL-P; and 9, 14, and 6% for large, medium, and small HDL-P,
respectively.
2.3. Statistical analysis
Analyses were performed using SAS, version 9.2. A two-sided test
with p b 0.05 was considered statistically signiﬁcant. For testing mul-
tiplicative interaction between biomarkers and diabetes in relation to
CHD risk, p b 0.10 was considered evidence of possible interaction,
which was then evaluated by diabetes-stratiﬁed models. Total and
HMW adiponectin, and physical activity were log-transformed for
analysis. HRs were calculated with Cox proportional hazards regres-
sion weighted by the inverse of the sampling fractions to account for
stratiﬁed sampling, and 95% conﬁdence intervals were calculated
using the robust variance estimator recommended for case–cohort
analysis [24]. Each risk marker was modeled separately, sequentially
adjusted for age and race, then BMI and WC, then smoking,hypertension, lipid-lowering medication, hormone therapy use, and
(log)physical activity. In the ﬁnal model all variables were adjusted
for each other and for the full covariate set. Sensitivity analyses
included stratifying by race-ethnicity and excluding users of lipid-
lowering medications and/or HT.
3. Results
Overall, at study baseline, the mean (SD) age of the study partici-
pants was 65.3 (6.9) years, 76.5% were hypertensive, 29.2% diabetic,
4.2% were current and 44% past smokers, 15.6% reported use of lipid-
lowering medications, and 33.7% reported current hormone treatment.
Mean (SD) follow-up time was 5.0 (1.8) years, 5.3 (1.5) for non-cases
and 3.7 (2.2) for CHD cases. Women with CHD events during follow-
up had similar mean age, BMI, WC, and prevalence of hypertension
but higher prevalence of diabetes (42% vs. 29%), current smoking
(8.3% vs. 3.9%) and lipid-lowering use (19.4% vs. 14.6%) compared to
their counterparts without events during follow-up (Table 1).
Compared with no CHD, severely obese postmenopausal women
with incident CHD had higher concentrations of total and small LDL-P,
and small VLDL-P, lower concentrations of total, large, and medium
HDL-P, smaller mean HDL-P size and LDL-P size, and lower mean levels
of leptin, total and large HDL-P, and small VLDL-P (Table 2). For all, HRs
for CHD per SD increase, were statistically signiﬁcant in separate
models, adjusted for age and race-ethnicity (Table 2). In contrast,
women with incident CHD had similar mean levels of total and HMW
adiponectin, large LDL-P and small HDL-P, compared with women
with no CHD. Assessed by stratiﬁed models and interaction terms (not
shown), biomarker associations with CHD risk were similar according
to baseline diabetes status, except for total and HMW adiponectin,
leptin, and large HDL-P, as described below.
Given evidence that associations of total and HMW adiponectin,
leptin, and large HDL-P with CHD differed by baseline diabetes status
(p b 0.10 for interaction terms) HRs adjusted for age, race-ethnicity,
BMI and WC were calculated separately by baseline diabetes status.
Among women without baseline diabetes (Table 3), levels of large
HDL-P were signiﬁcantly inversely related to CHD risk, but total and
HMW adiponectin and leptin were not signiﬁcantly related to CHD
risk. In contrast, among women with baseline diabetes, higher total
and HMW adiponectin and lower leptin were signiﬁcantly associated
with CHD risk, and large HDL-P was not. Results were similar when
evaluated as CHD rates/1000 PYs (Fig. 2), but for women with diabetes,
the increased risk of CHD was seen primarily in the highest quartiles of
total and HMW adiponectin, and the lowest quartile of leptin.
For biomarkerswithno interactionswith diabetes, associationswere
further evaluated in separate models, ﬁrst as quartiles, adjusted for age
and race, and then as continuous variables (per SD or log-unit increase),
Table 2
Biomarkers in relation to incident CHD among 677 postmenopausal women with BMI ≥ 40 kg/m2.
No CHD (n = 553) Incident CHD (n = 124) CHD risk per SD
Biomarker (SD) Mean (SD) Mean (SD) HR (95% CI)a
Leptin, ng/ml (23.2) 61.6 (23.0) 57.1 (23.8) 0.80 (0.67, 0.96c
Total adiponectin,b μg/ml 7.0 (3.9) 7.4 (5.2) 0.89 (0.66, 1.20)c
HMW adiponectinb, μg/ml 2.8 (2.3) 3.2 (3.3) 0.93 (0.68, 1.27)c
Total LDL-P, nmol/l (377) 1363 (360) 1515 (425) 1.41 (1.21, 1.65)
Large LDL-P, nmol/l (283.7) 562 (285) 551 (281) 1.01 (0.87, 1.10)
Small LDL-P, nmol/l (390.5) 620 (376) 775 (430) 1.40 (1.21, 1.64)
LDL size, nm (0.6) 20.9 (0.6) 20.8 (0.6) 0.85 (0.74, 0.98)
Total HDL-P, μmol/l (5.7) 33.6 (5.7) 32.1 (5.8) 0.69 (0.59, 0.81)
Large HDL-P, μmol/l (2.6) 4.9 (2.6) 3.9 (2.2) 0.70 (0.59, 0.83)c
Medium HDL-P, μmol/l (3.6) 8.8 (3.6) 7.8 (3.6) 0.66 (0.56, 0.77)
Small HDL-P, μmol/l (4.7) 20.0 (4.7) 20.4 (4.8) 1.05 (0.91, 1.20)
HDL size, nm (0.5) 9.0 (0.5) 8.9 (0.5) 0.74 (0.62, 0.87)
Total VLDL-P, nmol/l (33.3) 58 (32) 71 (37) 1.16 (0.99, 1.35)
Large VLDL-P, nmol/l (4.71) 5.0 (4.6) 6.5 (4.8) 1.02 (0.87, 1.20)
Medium VLDL-P, nmol/l (14) 18.7 (13.6) 23.1 (14.9) 1.06 (0.90, 1.25)
Small VLDL-P, nmol/l (20.9) 34.6 (20.0) 41.3 (23.7) 1.20 (1.02, 1.41)
VLDL Size, nm (7.2) 49.4 (7.1) 50.9 (7.3) 0.97 (0.82, 1.14)
a Age and race-adjusted hazard ratios (HR) and 95% conﬁdence intervals (CIs) calculated separately per 1 SD or 1 log-unit increase in each biomarker using Cox proportional hazard
regression, weighted for sampling, with standard errors/conﬁdence intervals calculated using robust estimator for case–cohort design. Signiﬁcant results are in bold.
b ln-transformed
c p b 0.10 for interaction with diabetes.
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small LDL-P (but not mean LDL size), lower levels of total and medium
HDL-P, and smallermeanHDL size each remained signiﬁcantly associat-
ed with CHD risk in all models.
We also evaluatedwhether associations of small LDL, HDL subclasses
or mean HDL particle size with CHD risk were independent of levels of
total HDL-P and LDL-P, with which they are correlated (Table 5). Over-
all, HRs for total LDL-P and total HDL-P remained statistically signiﬁcant
and were relatively unchanged when adjusted for each other or for
other lipoprotein parameters in multivariable-adjusted models. Inverse
associations of medium HDL-P with CHD also remained signiﬁcant
when adjusted for both total LDL-P and total HDL-P. In contrast, the pos-
itive association of small LDL-P with CHD was completely attenuated
when adjusted for total LDL-P. Likewise, the inverse association of
mean HDL size with CHD was not signiﬁcant if adjusted for total HDL-
P or total LDL-P, and was abolished (HR = ~1.0) if adjusted for both
HDL-P and LDL-P.
Finally, higher total LDL-P and lower total HDL-P independently
predicted CHD, adjusted for each other, age, race-ethnicity, BMI, WC,
physical activity, diabetes, smoking, hypertension, lipid-lowering med-
ication and hormone therapy (Table 6), with similar results if medium
HDL-P was substituted for total HDL-P. The risk of CHD was increased
by 50% (HR ≥ 1.50) for a 1 SD (377 nmol/l) increase in LDL-P, similar
to the 64% increase (HR 1.64) for Q4 vs. Q1 of LDL-P (Table 4), but also
close to the approximately 75% increase (HR 1.73) for diabetes vs. noTable 3
CHD risk (HRs (95% CI)) in relation to baseline biomarkers that differ by diabetes, among
677 postmenopausal women with BMI ≥ 40 kg/m2.
No baseline diabetes Baseline diabetes
N cases/total 72/467 52/210
Biomarker HR (95% CI) HR (95% CI)
Total adiponectin,a μg/ml 0.83 (0.55, 1.25) 1.79 (1.05, 3.07)
HMW adiponectin,a μg/ml 0.88 (0.53, 1.45) 2.07 (1.19, 3.61)
Leptin, ng/ml (23.2) 0.94 (0.76, 1.18) 0.69 (0.50, 0.96)
Large HDL-P, μmol/l (2.6) 0.69 (0.55, 0.86) 0.95 (0.66, 1.35)
HRs calculated separately for each biomarker adjusted for age, race-ethnicity, BMI and
waist circumference using Cox proportional hazard regression, weighted for sampling,
and with standard errors/conﬁdence intervals calculated using robust estimator for
case–cohort design. Results are reported for a 1 SD or 1 log-unit increase. Signiﬁcant re-
sults are in bold.
a ln-transformed.diabetes. Higher SBP, current smoking and less physical activity were
also signiﬁcantly associated with incident CHD. In sensitivity analyses
(not shown), restricted to those not using lipid-lowering medications
or HT, or to white women only, results were similar, except for weaker
associations of smaller LDL size with CHD risk when HT users were ex-
cluded. Among black women only, robust conclusions are precluded by
the low number of CHD cases, but differences inmean levels of total and
HMW adiponectin, leptin, total LDL-P, total and mediumHDL-P by inci-
dent CHD are similar to our overall results (not shown.)
Total and HMW adiponectin were correlated (Spearman) with each
other and various lipoproteins, as expected, e.g., associated with larger
mean LDL-P size and HDL-P size, lower levels of small LDL-P and higher
levels of large HDL-P (not shown). In contrast, leptin was uncorrelated
with most risk factors. Correlations were similar when stratiﬁed by dia-
betes or whenwomen using lipid-loweringmedications were excluded
(not shown). Evaluation of participant characteristics by adiponectin or
leptin quartiles among women with diabetes also revealed no factors
which explained the paradoxical associations with CHD risk.
4. Discussion
Among these severely obese postmenopausal women, higher
concentrations of LDL-P and lower concentrations of HDL-P (total and
medium) were the strongest determinants of CHD risk, independent
of BMI, WC, diabetes, SBP, smoking, physical activity, and use of anti-
hypertensive and lipid-lowering medications and HT. In contrast, asso-
ciations of leptin, total and HMW adiponectin with CHD risk differed by
baseline diabetes status. Among women without diabetes, leptin, total
and HMW adiponectin were not signiﬁcantly associated with CHD
risk, whereas among women with diabetes, lower leptin and higher
total and HMW adiponectin were paradoxically associated with CHD
risk. These results are consistent with studies of average-weight adults,
which show robust associations of atherosclerosis and CHD risk with
higher concentrations of LDL-P [12,15–17,19,20,30] and lower concen-
trations of total HDL-P [11–14,18,21] and medium HDL-P [12,13].
These studies have also found that inverse associations of total and
medium HDL-P with CHD, CVD, and atherosclerosis are relatively inde-
pendent of atherogenic lipoprotein particles (LDL-P or apoB), and other
lipids [11,12,18,21]. In contrast, associations of mean LDL size, HDL size,
large HDL-P, and HDL-C with CHD are substantially attenuated when
adjusted for concentrations of lipoproteins (LDL-P and HDL-P) or apoli-
poproteins (apoB and apoA-1) [11,12,14,18,19,21,22]. Our study also
Fig. 2. Incident CHD rates per 1000 person-years (PY) by quartiles of total and HMWadiponectin, leptin and large HDL-P, stratiﬁed by baseline diabetes status. A. Total Adiponectin: quar-
tiles are b4.3, 4.3–b6.2, 6.2–b8.6 and N= 8.6 μg/ml. B. HMW adiponectin; quartiles are b1.4, 1.4–b2.4, 2.4–N3.7 and N=3.7 μg/ml; C. leptin: quartiles are b45.4, 45.4–b57, 57–b74.6 and
≥74.6 ng/ml; D. large HDL-P: quartiles are b2.8, 2.8–b4.2, 2.8–b6 and N=6 μmol/l.
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weaker for severely obese postmenopausal women with, than without,
diabetes, consistent with evidence that larger HDL particles may be
more susceptible to dysfunction in diabetes than smaller HDL particles
[31,32].
Among severely obese postmenopausal women with diabetes only,
higher total and HMW adiponectin and lower leptin were associated
with CHD risk, whereas among women without diabetes, associations
were weakly protective (adiponectin) or non-existent (leptin). Previous
studies have reported similar null or paradoxical associations of higher
total and HMW adiponectin with CHD and total mortality among older
and high-risk adults [7–9,33–36]. As in studies of average-weight adults
[35], associations of total and HMW adiponectin with lowerWC, insulin
resistance, and better lipoprotein levels did not explain their paradoxical
associations with higher CHD risk among severely obese women with
diabetes. These paradoxical associations with adiponectin may be due
to increases in adiponectin in compensation for existing disease, rather
than to adverse causal effects of higher adiponectin levels. Indeed,
brain natriuretic peptide (BNP), which is increased in heart failure, isTable 4
Incident CHD risk (HR (95% CI)) by baseline biomarkers, among 677 postmenopausal women
Model 1: adjusteda HR (95% CI) by quartiles
Predictor Q1 Q2
Total LDL-P, nmol/l b1129 1129–b1368
HR (95% CI) 1.0 1.41 (0.91–2.18)
Small LDL-P, nmol/l b428 428–b634
HR (95% CI) 1.0 0.90 (0.59–1.35)
LDL size, nm b20.5 20.5–b21
HR (95% CI) 1.0 0.96 (0.64–1.43)
Total HDL-P, μmol/l b29.5 29.5–b33
HR (95% CI) 1.0 0.53 (0.35–0.80)
Medium HDL-P, μmol/l b6 6–b8.4
HR (95% CI) 1.0 0.61 (0.40–0.94)
HDL size, nm (0.5) b8.7 8.7–b9
HR (95% CI) 1.0 0.86 (0.59–1.28)
Small VLDL-P, nmol/l b20.3 20.3–b33.3
HR (95% CI) 1.0 0.35 (0.22–0.54)
HRs from separate Cox models. Signiﬁcant results are in bold.
a Adjusted for age and race.
b Adjusted for age, race, BMI and waist circumference.also correlated with, and stimulates, adiponectin release [37], and
adjusting for BNP partially attenuates the positive associations of
adiponectin with CHD and CVD [34,36]. As noted, the complexities of
adiponectin in relation to outcomes were also reported in the SOS
Study, which found that baseline and 2 year changes in adiponectin
were associated with incident MI and incident diabetes among the
obese adults who did not receive bariatric surgery (control group), but
not among those who received bariatric surgery [10].
Among the severely obese women in the current study, for those
with diabetes, low leptin was associated with increased CHD rates,
whereas most prior studies among average weight individuals have
reported positive or null associations with CHD risk [6]. However, one
study of overweight middle-aged women with a high prevalence of
diabetes and impaired glucose tolerance found that low leptinwas asso-
ciated with CVD mortality [38]. Furthermore, in MESA, adjusted for
weight and height, higher leptin was associated with smaller left ven-
tricularmass and better left ventricular function [39].We foundnomea-
sured risk factors that explained our results, and additional studies are
needed to verify whether the protective association of leptin withwith BMI ≥ 40 kg/m2.
Model 2: adjustedb
HR (95% CI) per SD
Q3 Q4
1368–b1598 N1598 1.41 (1.21–1.65)
1.72 (1.08–2.73) 1.64 (1.05–2.55)
634–b871 N871 1.34 (1.13–1.59)
1.59 (1.03–2.46) 1.71 (1.15–2.53)
21–b21.4 N21.4 0.92 (0.79–1.08)
0.83 (0.55–1.25) 0.53 (0.34–0.83)
33–b36.9 N36.9 0.73 (0.62–0.87)
0.79 (0.52–1.18) 0.35 (0.23–0.53)
8.4–b11 N11 0.67 (0.57–0.79)
0.61 (0.41–0.91) 0.40 (0.27–0.60)
8.7–b9.3 N9.3 0.80 (0.66–0.96)
0.60 (0.41–0.89) 0.53 (0.35–0.81)
20.3–b48.2 N48.2 1.16 (0.98–1.37)
0.64 (0.42–0.99) 0.99 (0.64–1.52)
Table 5
CHD risk (HR (95% CI)) per SD increase in lipoproteins modeled separately and jointly, among postmenopausal women with BMI ≥ 40 kg/m2, n = 677.
Predictors Total LDL-P Small LDL-P Mean HDL size Med. HDL-P Total HDL-P
Modeled separately 1.61 (1.35, 1.93) 1.45 (1.21, 1.75) 0.69 (0.55, 0.87) 0.66 (0.55, 0.80) 0.68 (0.56, 0.83)
Modeled jointly
LDL-P + HDL-P 1.68 (1.39, 2.03) 0.72 (0.58, 0.91)
Small LDL-P + LDL-P 1.64 (1.25, 2.13) 1.04 (0.77, 1.39)
HDL size + HDL-P 0.78 (0.59, 1.02) 0.75 (0.60, 0.95)
HDL size + LDL-P 1.63 (1.33, 2.00) 0.89 (0.66, 1.20)
HDL size + HDL-P + LDL-P 1.67 (1.36, 2.05) 0.97 (0.71, 1.33) 0.73 (0.57, 0.93)
Med. HDL-P + total HDL-P 0.77 (0.64, 0.94) 0.84 (0.67, 1.05)
Med. HDL-P + total LDL-P 1.57 (1.30, 1.88) 0.72 (0.60, 0.87)
Med. HDL-P + total HDL-P + Total LDL-P 1.57 (1.30, 1.88) 0.79 (0.64, 0.97) 0.84 (0.66,1.07)
All models are adjusted for age, race-ethnicity, BMI, waist circumference, smoking, diabetes, hypertension, physical activity, lipid-lowering, hormone therapy. Signiﬁcant results are in bold.
248 R.H. Mackey et al. / BBA Clinical 3 (2015) 243–250CHD among severely obese women with diabetes is real or due to un-
measured confounding or chance.
The results of this study should be interpreted in light of its strengths
and limitations. TheWHI-OS offers a rare opportunity to evaluate factors
related to incident CHD among a large sample of severely obese women
not selected for bariatric surgery, and with a relatively low prevalence of
statin use at baseline. The biomarkers included have high potential clin-
ical relevance and were measured in well-established laboratories
blinded to study outcomes. However, as in all observational studies, our
study is subject to potential unmeasured or residual confounding. Fur-
thermore, of the 1852 WHI participants eligible for our study, only 371
(8%) were black, with 23 incident CHD cases, limiting the power for
CHD analyses restricted to black women only. However, in sensitivity
analyses (not shown), key predictors had similar direction of association
with CHDwhen restricted to black women only, which agrees with a re-
cent report showing that HDL-P was inversely associated with CHD risk
among black and white adults, whereas HDL-C was associated with risk
only among white adults [18]. Finally, due to cost and specimen volume
limitations, the current study did not measure lipids or apolipoproteins,
so it cannot compare the predictive ability of LDL-P andHDL-Pwith lipids
(LDL-C, HDL-C, non-HDL-C, etc.) or apolipoproteins (apoB, apoA-1, etc.)4.1. Clinical implications
Given the higher prevalence of severe obesity among women, se-
verely obese women form one of the largest subgroups of women
with high CVD risk, since we have previously shown that CHD, CVD
andmortality rates among postmenopausal womenwith severe obesity
are two-fold higher than women with normal BMI, and are even higher
with concomitant diabetes, hypertension and/or smoking [3]. Hyperten-
sion and diabetes are both very common in severe obesity, with a prev-
alence of N60% and ~30%, respectively, in the current study, and among
younger severely obese adults [40]. The current study adds that among
severely obese postmenopausal women, regardless of diabetes and
other CV risk factors, higher levels of LDL-P and lower levels of HDL-P
are also strongly related to CHD risk, but levels of large LDL-P, which
are strongly correlated with LDL-C (not measured in this study), areTable 6
HRs (95% CIs) for the risk of incident CHD according to baseline biomarkers in multivari-
able-adjusted models, among 677 postmenopausal women with BMI ≥ 40 kg/m2.
Predictor (SD) Model 1 Model 2
Total LDL-P, nmol/l (377) 1.55 (1.28, 1.88) 1.50 (1.24, 1.82)
Total HDL-P, μmol/l (5.7) 0.70 (0.57, 0.85) –
Medium HDL-P, μmol/l (4.0) – 0.63 (0.51, 0.78)
Type 2 diabetes (vs. no) 1.73 (1.17, 2.56) 1.74 (1.18, 2.59)
Systolic blood pressure (17 mm Hg) 1.11 (1.02, 1.20) 1.09 (1.01, 1.19)
Current smoking (vs never) 2.99 (1.41, 5.97) 2.53 (1.23, 5.22)
(Log) physical activity, met/h/wk 0.85 (0.73, 0.99) 0.85 ,0.72, 0.99)
Hazard ratios calculated per SD increase in biomarkers adjusted for each other and age,
race-ethnicity, BMI, waist circumference, use of anti-hypertensive and lipid-lowering
medications and hormone therapy. Signiﬁcant results are in bold.not signiﬁcantly related to CHD risk. Mean LDL-P levels among severely
obese postmenopausal women in our study were substantially higher
than clinical recommendations (low risk b1000 nmol/l) [41], average-
weight women [30], and adults in MESA [29]. In contrast, mean levels
of large LDL-P (highly correlated with LDL-C) were lower among these
severely obesewomen than among individuals inMESA [29], congruent
with reports that hypercholesterolemia is not increased among severely
obese postmenopausal women [40,42,43]. Furthermore, the Study of
Women Across the Nation showed that although apoB, total cholesterol
and LDL-C increase across the menopausal transition, the increase was
substantially ﬂattened for women in the heaviest tertile of weight [44].
Although we did not measure LDL-C in this study, these prior studies
suggest that among severely obese postmenopausal women, levels of
total or LDL cholesterol may not reliably indicate CHD risk related to
LDL lipoproteins. However, the current study shows that higher levels
of LDL measured by LDL-P are independently associated with incident
CHD among severely obese postmenopausal women, as previously
shown for average weight women [16].
An important issue is whether all individuals with severe (class III)
obesity should be considered at high CHD risk and be offered statin
drug therapy as well as treatment of hypertension and smoking cessa-
tion. We have also previously shown that among younger severely
obese adults (predominantly middle-aged women) in a multicenter
US bariatric surgery study, the majority of those without diabetes
have low 10-year Framingham risk, but high lifetime predicted CVD
risk [40]. Mean HDL-P levels in these severely obese postmenopausal
women were also lower than levels reported in MESA [29]. Lifestyle in-
tervention among overweight and obese postmenopausal women can
decrease LDL-P [45], but effects are small relative to those of statins,
which reduce LDL-P as well as LDL-C, and also raise HDL-P [14,46]. Clin-
ical trial data demonstrate substantial reductions in CHD events with
lipid-lowering therapy among women [47]. Bariatric surgery has been
documented to successfully reduce body weight and diabetes mellitus,
but in a non-randomized study, SOS, the incidence of CVD diverged
only in very long-term follow-up, and incidentMI and CVDwere related
to baseline total cholesterol, diabetes, and smoking rather than to base-
lineHDL-C, BMI, or 2 yearweight change [4]. However, there are no ran-
domized clinical trials that show that bariatric surgery reduces
incidence of CHD or CHD mortality, especially in long term. It is very
unlikely that such trials will be done in the foreseeable future.5. Conclusions
In summary, postmenopausal women with severe obesity
(BMI ≥ 40 kg/m2) have a high risk of CHD, driven by smoking, diabe-
tes and hypertension [3], and as shown in this study, higher levels of
LDL-P and lower levels of HDL-P, which are modiﬁable by statin use.
The current study also suggests that among severely obese postmen-
opausal women, leptin and total and HMWadiponectin have complex
relations to CHD risk that complicate use for risk assessment and as
potential treatment targets. Prevention of CHD, as well as stroke and
249R.H. Mackey et al. / BBA Clinical 3 (2015) 243–250heart failure in severe obesity is likely feasible and should be a very
high priority in prevention therapy, especially among the increasing
proportion of women with severe obesity.
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